JOBY vs IONS Comparison

Joby Aviation Inc is a transportation company developing an all-electric, vertical take-off and landing (eVTOL) air taxi for commercial passenger service. Its Joby eVTOL aircraft is designed to transport a pilot and up to four passengers or an expected payload of up to 1,000 pounds at speeds of up to 200 mph. The aircraft is optimized for urban routes, with a target range of up to 100 miles on a single charge. The company is also developing an app-based platform to build and operate an aerial ridesharing service powered by a network of eVTOL aircraft that it will manufacture and operate. It has one operating and reportable segment, namely flight services. Currently, the company generates all of its revenue from flight services provided to the Department of Defense in the United States.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.